1. Scrip
  2. >>Business

Shire Outlines Baxalta Integration Strategy

 
• By Joseph Haas

First quarter financial results brought another growth period for Shire PLC, but perhaps the most noteworthy information provided by the company on its April 29 earnings call, was its strategy for integrating Baxalta Inc. into its infrastructure, assuming both companies' boards approve the transaction when they meet separately on May 27.

Overall, the Dublin-headquartered specialty firm reported product sales of $1.627bn for the first quarter of 2016, up 14% year-over-year. As usual, the top-seller was attention-deficit/hyperactivity disorder (ADHD) stalwart Vyvanse (lisdexamfetamine), which posted 22% growth to $509m on the quarter. It also was a strong quarter for Shire's hereditary angioedema franchise, as Firazyr (icatibant) sales increased 39% to $128m and Cinryze (C1 esterase inhibitor) sales rose 11% to $164m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from Scrip

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.